Get the Stockscreener App
35.92
6.18%
2.09
After Hours:
36.08
0.16
+0.45%
Dyne Therapeutics Inc stock is traded at $35.92, with a volume of 1.27M.
It is up +6.18% in the last 24 hours and down -22.07% over the past month.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
See More
Previous Close:
$33.83
Open:
$33.68
24h Volume:
1.27M
Relative Volume:
0.98
Market Cap:
$3.56B
Revenue:
-
Net Income/Loss:
$-257.60M
P/E Ratio:
-10.56
EPS:
-3.4
Net Cash Flow:
$-220.31M
1W Performance:
+3.73%
1M Performance:
-22.07%
6M Performance:
+26.52%
1Y Performance:
+300.89%
1-Day Range:
$33.45
$36.09
1-Week Range:
$32.18
$36.09
52-Week Range:
$6.40
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Marshall Wace LLP Purchases 219,862 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 11.5% in September - MarketBeat
(DYN) Proactive Strategies - Stock Traders Daily
Axa S.A. Sells 68,417 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 2,357 Shares of Stock - MarketBeat
Renaissance Technologies LLC Invests $4.45 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne therapeutics director sells over $127k in company stock - Investing.com India
Dyne therapeutics director sells over $127k in company stock By Investing.com - Investing.com South Africa
Dyne therapeutics director sells over $127k in company stock By Investing.com - Investing.com Australia
Dyne therapeutics director sells over $127k in company stock By Investing.com - Investing.com Canada
Dyne therapeutics director sells over $127k in company stock - Investing.com
Dyne therapeutics director sells over $127k in company stock By Investing.com - Investing.com UK
Dyne Therapeutics Inc: Navigating a Turbulent Year, Up -26.49% from 52-Week Low - The InvestChronicle
It makes sense and dollars to buy Dyne Therapeutics Inc (DYN) stock - SETE News
Armistice Capital LLC Lowers Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
Ensign Peak Advisors Inc Sells 298,541 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
What is the investor’s view on Dyne Therapeutics Inc (DYN)? - US Post News
Affinity Asset Advisors LLC Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Analysts review Dyne Therapeutics Inc’s rating - Knox Daily
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 3% - MarketBeat
Quarterly Snapshot: Quick and Current Ratios for Dyne Therapeutics Inc (DYN) - The Dwinnex
First Light Asset Management LLC Grows Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Integral Health Asset Management LLC Acquires Shares of 100,000 Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
100,000 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Integral Health Asset Management LLC - Defense World
Piper Sandler maintains overweight rating on Dyne Therapeutics shares By Investing.com - Investing.com UK
Dyne Therapeutics’ (DYN) “Overweight” Rating Reaffirmed at Piper Sandler - Defense World
Dyne Therapeutics' (DYN) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference - GlobeNewswire
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference - StockTitan
Avoro Capital Advisors LLC Acquires New Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Victory Capital Management Inc. Acquires Shares of 19,152 Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Victory Capital Management Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $51.40 Average PT from Analysts - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Buy” by Analysts - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Dyne, Napco, and Franklin and Encourages Investors to Contact the Firm - GlobeNewswire
Dirk Kersten, director at Dyne Therapeutics, sells over $2.9m in stock By Investing.com - Investing.com South Africa
Dirk Kersten, director at Dyne Therapeutics, sells over $2.9m in stock - Investing.com Australia
Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,390 Shares of Stock - Defense World
Dirk Kersten, director at Dyne Therapeutics, sells over $2.9m in stock - Investing.com
Dirk Kersten, director at Dyne Therapeutics, sells over $2.9m in stock - Investing.com UK
Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High Sells 8,976 Shares - Defense World
Dyne Therapeutics Inc (DYN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Dyne therapeutics CSO sells shares worth over $80,000 - Investing.com India
Dyne Therapeutics Inc [DYN] Officer makes an insider purchase of 1,390 shares worth 47964.0. - Knox Daily
Richard William Scalzo Sells 1,390 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - MarketBeat
Dyne therapeutics CSO sells shares worth over $80,000 By Investing.com - Investing.com South Africa
Dyne Therapeutics COO sells over $300,000 in company stock By Investing.com - Investing.com South Africa
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kersten Dirk | Director |
Sep 26 '24 |
Sale |
35.29 |
1,260 |
44,465 |
189,679 |
| Kersten Dirk | Director |
Sep 20 '24 |
Sale |
36.45 |
79,411 |
2,894,795 |
234,127 |
| Kersten Dirk | Director |
Sep 23 '24 |
Sale |
35.32 |
40,831 |
1,442,098 |
193,296 |
| Kersten Dirk | Director |
Sep 19 '24 |
Sale |
36.17 |
78,739 |
2,848,283 |
313,538 |
| Kersten Dirk | Director |
Sep 18 '24 |
Sale |
35.03 |
1,554 |
54,437 |
392,277 |
| HIGH SUSANNA GATTI | Chief Operating Officer |
Sep 18 '24 |
Sale |
34.41 |
8,976 |
308,864 |
131,636 |
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Sep 18 '24 |
Sale |
34.55 |
1,390 |
48,024 |
98,568 |
| Beskrovnaya Oxana | Chief Scientific Officer |
Sep 18 '24 |
Sale |
34.55 |
2,339 |
80,812 |
140,375 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):